A female doctor explains a procedure to a patient
A female doctor explains a procedure to a patient

Retinal Conditions

Explore our product portfolio.

40 mg/mL box of Xipere™ Injectable Suspention
40 mg/mL box of Xipere™ Injectable Suspention

XIPERE®

(triamcinolone acetonide injectable suspension), for suprachoroidal use 40 mg/mL

15 mg bottle of Bausch + Lomb Visudyne®
15 mg bottle of Bausch + Lomb Visudyne®

VISUDYNE®

(verteporfin for injection) 15 mg

Bausch + Lomb Retisert® Implant, 0.59 mg
Bausch + Lomb Retisert® Implant, 0.59 mg

RETISERT®

(fluocinolone acetonide intravitreal implant) 0.59 mg

XIPERE®
IMPORTANT SAFETY INFORMATION

  • Your eye doctor will monitor you for elevated eye pressure following treatment and manage it with medication or surgery if required.
  • See your eye doctor right away if your eyes become red, sensitive to light or painful, or if you notice changes in vision.
  • XIPERE is not appropriate for use in patients with eye infections. It should be used with caution in patients with a history of herpes simplex in the eye.
  • XIPERE is not appropriate for use in patients with a known allergy to triamcinolone acetonide or any other components of this product.
  • Use of corticosteroids such as XIPERE may produce cataracts, increased eye pressure and glaucoma, and may increase the likelihood of eye infections.
  • Patients being treated with XIPERE for extended periods of time will be monitored for problems with the body’s hormonal system, which controls the ability to respond to stress.
  • In clinical studies, the most common eye-related side effects were increased eye pressure and eye pain. Other side effects included cataract, floaters or flashes of light, injection site pain, burst blood vessels, reduced or blurred vision, dry eye, light sensitivity, redness, infection, swelling, watery eyes, eye or eyelid irritation, bumps on the eyelid, itchy eyes, and drooping eyelid.
    The most common non-eye-related side effect was headache.
  • Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant. Talk to your eye doctor.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information for XIPERE®.

VISUDYNE®
IMPORTANT SAFETY INFORMATION

  • VISUDYNE® (verteporfin for injection) should not be used if you have a condition known as porphyria (blood enzyme deficiency), or if you are allergic to it or any of its components.
  • If there is leakage of medication into the tissue around the injection site, it may cause damage. If this happens, protect the area from direct light until swelling and discoloration have faded.
  • Avoid exposure of skin and eyes to direct sunlight or bright indoor light for 5 days after treatment with VISUDYNE®. Wear protective clothes and dark sunglasses if going outdoors during this time. A UV sunscreen will not offer enough protection for your skin. Wear a wristband to remind you to do this. However, do not stay in totally dark areas. You should expose your skin to regular indoor and/or indirect light because doing so will help inactivate the drug in your skin.
  • In clinical studies, the most common side effects were injection site reactions (such as pain, redness, irritation, rashes and swelling) or changes in vision (including blurred vision and flashes of light). Tell your doctor about any side effects that you may have.
  • If you develop or have changes or a decrease in vision after treatment, do not drive or use machines as long as these symptoms continue.

You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or 1-800-FDA-1088

Please click here for full Prescribing Information for VISUDYNE®.

RETISERT®
IMPORTANT SAFETY INFORMATION

  • RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg should not be used if you have an infection of the eye from viruses, bacteria, fungi or fungal diseases.
  • After receiving the RETISERT® implant, you should periodically see an eye doctor for follow‐up examinations of both eyes.
  • As with any surgical procedure, there is risk involved. Complications can include injury to the eye; infection; mechanical complication, movement or ejection of the implant; and wound complications following the surgery.
  • After receiving the RETISERT® implant, nearly all patients will experience an immediate and temporary decrease in vision in the implanted eye that lasts for approximately 1 to 4 weeks following the surgery.
  • Based on clinical studies, within 3 years after receiving the RETISERT® implant, approximately 77% of patients require medications to lower pressure in the eye and approximately 37% of patients will require a surgical procedure to control pressure in the eye.
  • Long‐term use of corticosteroids may result in an increased risk of glaucoma (high pressure in the eye).
  • Based on clinical studies, within 3 years after receiving the RETISERT® implant, nearly all patients who have not already had cataracts will develop them and require surgery.
  • The most common side effects, occurring in 50‐90% of patients, were cataract, increased pressure in the eye, surgery complications and eye pain. Headache was also reported in 33% of patients.

Please click here for full Prescribing Information for RETISERT®.